IP Library Granted Patent US 7,615,632
Granted Patent B2
US 7,615,632 · App. 11/024,443 · Granted Nov 10, 2009

Crystalline forms of temozolomide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,632
App. No.
11/024,443
Granted
Nov 10, 2009
Kind
B2
Abstract

Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions.

Claims (11)

1. Crystalline Temozolomide Form III comprising at least one of the characteristics selected from the group consisting of:

a powder X-ray diffraction pattern exhibiting peaks at diffraction angles 2θ of about 10.8, 13.2, 14.7, 16.2, 16.8, 18, 19.1, 19.6, 21.5, 26.6, 23.8, 28.8, 29.8±0.2°; and

an infrared spectrum with ν max at about 1678, 731 and 712±4 cm −1 .

2. The crystalline Temozolomide of claim 1 , wherein said powder X-ray diffraction pattern is substantially as depicted in FIG. 6 .

3. The crystalline Temozolomide of claim 1 , wherein said infrared spectrum is substantially as depicted in FIG. 7 .

4. A process of preparing crystalline Temozolomide Form III, the process comprising:

contacting Temozolomide with a solvent, said solvent including at least one solvent component selected from the group consisting of dimethylformamide, ethanol, and a mixture of benzyl alcohol and isopropanol, to thereby form a Temozolomide solution;

crystallizing said Temozolomide in said solution, to thereby obtain the crystalline Temozolomide Form III; and

isolating the crystalline Temozolomide Form III.

5. A process of preparing crystalline Temozolomide Form III, the process comprising

heating crystalline Temozolomide Form II to a transubstantiation temperature of about 120° C., to thereby obtain the crystalline Temozolomide Form III, wherein the Form II precursor exhibits a powder X-ray diffraction pattern with peaks at diffraction angles 2θ of about 10.8, 11.3, 14.5, 16.0, 17.9 and 19.1±0.2° or exhibits an infrared spectrum with ν max at about 3451, 1749 and 1736±4 cm −1 , and the Form III product exhibits a powder X-ray diffraction pattern with peaks at diffraction angles 2θ of about 10.8, 13.2, 14.7, 16.2, 16.8, 18, 19.1, 19.6, 21.5, 26.6, 23.8, 28.8, 29.8±0.2° or exhibits an infrared spectrum with ν max at about 1678, 731 and 712±4 cm −1 .

Assignments (3)
CHANGE OF NAME Recorded Mar 28, 2018
From: PERRIGO API LTD
To: WAVELENGTH ENTERPRISES LTD
Reel/Frame 045369/0829 →
CHANGE OF NAME Recorded May 22, 2014
From: CHEMAGIS LTD.
To: PERRIGO API LTD.
Reel/Frame 032995/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2005
From: ADIN, ITAI; IUSTAIN, CARMEN
To: CHEMAGIS LTD.
Reel/Frame 016381/0038 →